Cargando…
AR-V7 biomarker testing for primary prostate cancer: The ongoing challenge of analytical validation and clinical qualification
Autores principales: | Sowalsky, Adam G., Sharp, Adam, Trostel, Shana Y., de Bono, Johann S., Plymate, Stephen R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8114102/ https://www.ncbi.nlm.nih.gov/pubmed/33516656 http://dx.doi.org/10.1016/j.ctarc.2020.100218 |
Ejemplares similares
-
Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer
por: Welti, Jonathan, et al.
Publicado: (2016) -
MEIS1 down-regulation by MYC mediates prostate cancer development through elevated HOXB13 expression and AR activity
por: Whitlock, Nichelle C., et al.
Publicado: (2020) -
Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer
por: Sowalsky, Adam G., et al.
Publicado: (2022) -
Performance qualification: Critical to validation
por: Agnihotri, Ajju, et al.
Publicado: (2013) -
Identification of AR-V7 downstream genes commonly targeted by AR/AR-V7 and specifically targeted by AR-V7 in castration resistant prostate cancer
por: Sugiura, Masahiro, et al.
Publicado: (2020)